Gabriella Spaltro1, Stefania Straino2, Elisa Gambini3, Beatrice Bassetti3, Luca Persico4, Stefano Zoli5, Marco Zanobini5, Maurizio C Capogrossi6, Rita Spirito5, Cinzia Quarti7, Giulio Pompilio8. 1. Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino, IRCCS, Milan, Italy. Electronic address: gspaltro@ccfm.it. 2. Laboratory of Vascular Pathology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy; Explora Biotech srl, Rome, Italy. 3. Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino, IRCCS, Milan, Italy. 4. DIEC-Dipartimento di Economia, Università degli Studi di Genova, Genoa, Italy. 5. Department of Cardiovascular Surgery, University of Milan, Centro Cardiologico Monzino, IRCCS, Milan, Italy. 6. Laboratory of Vascular Pathology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy. 7. Medical Division, Pall Italia srl, Italy. 8. Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Abstract
BACKGROUND AIMS: The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency. METHODS: PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemia mouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution. RESULTS: Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia. CONCLUSIONS: The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.
BACKGROUND AIMS: The Pall Celeris system is a filtration-based point-of-care device designed to obtain a high concentrate of peripheral blood total nucleated cells (PB-TNCs). We have characterized the Pall Celeris-derived TNCs for their in vitro and in vivo angiogenic potency. METHODS: PB-TNCs isolated from healthy donors were characterized through the use of flow cytometry and functional assays, aiming to assess migratory capacity, ability to form capillary-like structures, endothelial trans-differentiation and paracrine factor secretion. In a hind limb ischemiamouse model, we evaluated perfusion immediately and 7 days after surgery, along with capillary, arteriole and regenerative fiber density and local bio-distribution. RESULTS:Human PB-TNCs isolated by use of the Pall Celeris filtration system were shown to secrete a panel of angiogenic factors and migrate in response to vascular endothelial growth factor and stromal-derived factor-1 stimuli. Moreover, after injection in a mouse model of hind limb ischemia, PB-TNCs induced neovascularization by increasing capillary, arteriole and regenerative fiber numbers, with human cells detected in murine tissue up to 7 days after ischemia. CONCLUSIONS: The Pall Celeris system may represent a novel, effective and reliable point-of-care device to obtain a PB-derived cell product with adequate potency for therapeutic angiogenesis.
Authors: Laura Rehak; Laura Giurato; Marco Meloni; Andrea Panunzi; Giada Maria Manti; Luigi Uccioli Journal: J Clin Med Date: 2022-02-08 Impact factor: 4.241
Authors: Gaia Spinetti; Carlo Maria Ferdinando Caravaggi; Andrea Panunzi; Fabiana Madotto; Elena Sangalli; Federica Riccio; Adriana Barbara Sganzaroli; Paolo Galenda; Amelia Bertulessi; Maria Francesca Barmina; Ornella Ludovico; Orazio Fortunato; Francesco Setacci; Flavio Airoldi; Davide Tavano; Laura Giurato; Marco Meloni; Luigi Uccioli; Antonino Bruno Journal: Cardiovasc Diabetol Date: 2022-09-28 Impact factor: 8.949